Facet Life Sciences Partners with Nucleus to Advance Radiopharmaceutical Development Through Regulatory Expertise
核心洞察
Facet Life Sciences (搜索) has announced a strategic partnership with Nucleus (搜索), a leader in diagnostic and therapeutic radiopharmaceuticals (搜索), to serve as their official regulatory partner for U.S. FDA affairs.
Facet's regulatory team brings extensive experience with over 40 FDA applications submitted including INDs, NDAs, BLAs, and ANDAs, plus leadership of more than 75 FDA meetings across multiple divisions.
The partnership aims to accelerate radiopharmaceutical product development by providing critical regulatory guidance and ensuring effective navigation of the FDA approval process.
Facet Life Sciences (搜索), a Phoenixville-based firm specializing in regulatory guidance for life science companies, has announced a strategic partnership with Nucleus (搜索), a leader in diagnostic and therapeutic radiopharmaceuticals (搜索). Under this collaboration, Facet will serve as Nucleus' official regulatory partner, providing comprehensive expertise in U.S. regulatory affairs and development support for innovative radiopharmaceutical products.
Extensive FDA Experience Drives Partnership Value
Facet's regulatory team brings substantial experience to the partnership, having prepared and submitted over 40 applications to the U.S. Food and Drug Administration (FDA). These submissions span multiple application types including Investigational New Drugs (IND), New Drug Applications (NDA), Biologics License Applications (BLA), and Abbreviated New Drug Applications (ANDA).
The team's expertise extends beyond submissions to direct FDA engagement, having led more than 75 FDA meetings involving various divisions including the Center for Drug Evaluation and Research (搜索) (CDER), the Center for Biologics Evaluation and Research (搜索) (CBER), and the Office of Generic Drugs (搜索) (OGD).
Recognized Expertise in Radiopharmaceuticals
Both the FDA and the Society of Nuclear Medicine and Molecular Imaging (搜索) (SNMMI) recognize Facet as experts in diagnostic and therapeutic radiopharmaceuticals (搜索), positioning the company to provide specialized guidance in this complex regulatory landscape. This recognition underscores Facet's deep understanding of the unique challenges and requirements associated with radiopharmaceutical development.
Ken VanLuvanee, President & CEO of Facet Life Sciences (搜索), emphasized the strategic importance of the partnership. "We are thrilled to join forces with Nucleus (搜索) as their official regulatory partner," VanLuvanee stated. "Our team brings extensive experience in regulatory strategy, medical writing, and submissions to help life science companies manage the intricacies of FDA interactions. We are excited to apply our expertise in the radiopharmaceutical space and support Nucleus and their clients in advancing innovative products to and through FDA."
Strategic Focus on Accelerating Development
The partnership represents a focused effort to accelerate the development of radiopharmaceutical products by ensuring effective navigation of the FDA approval process. Facet's regulatory approach will provide Nucleus (搜索) with critical guidance throughout the development lifecycle, from early-stage regulatory strategy through final approval.
This collaboration highlights both companies' commitment to advancing life-saving therapies in the radiopharmaceutical sector. The partnership aims to drive innovation and bring cutting-edge medical advancements to market more efficiently by leveraging Facet's proven regulatory expertise and Nucleus (搜索)' leadership in radiopharmaceutical development.